Leite E B, Mota M C, de Abreu J R, Cunha-Vaz J G
Department of Ophthalmology, University of Coimbra, Portugal.
Int Ophthalmol. 1990 Mar;14(2):81-8. doi: 10.1007/BF00154206.
The effect of calcium dobesilate on the alteration of the blood-retinal barrier was studied in 41 adult-onset, non-insulin dependent diabetic patients with minimal or no retinopathy, randomly assigned to receive either oral calcium dobesilate (1000 mg twice daily) or a placebo for 12 months. The posterior vitreous value and the penetration ratio, determined by vitreous fluorophotometry, reflected stabilisation of blood-retinal barrier permeability in the calcium dobesilate patients and deterioration of blood retinal barrier in those given placebo. During the relatively short period of the study, one year, no significant change in microaneurysm and capillary closure gradings was observed. No side effects were associated with calcium dobesilate.
在41例成年发病、非胰岛素依赖型糖尿病且视网膜病变轻微或无病变的患者中，研究了羟苯磺酸钙对血视网膜屏障改变的影响。这些患者被随机分配接受口服羟苯磺酸钙（每日两次，每次1000毫克）或安慰剂，为期12个月。通过玻璃体荧光光度法测定的玻璃体后段值和渗透比，反映了服用羟苯磺酸钙患者血视网膜屏障通透性的稳定以及服用安慰剂患者血视网膜屏障的恶化。在相对较短的一年研究期间，未观察到微动脉瘤和毛细血管闭塞分级有显著变化。羟苯磺酸钙未出现任何副作用。
